. "Dalfopristina"@en . . . . . "The site of action of dalfopristin is the bacterial ribosome. Dalfopristin has been shown to inhibit the early phase of protein synthesis. "@en . "For the treatment of bacterial infections (usually in combination with quinupristin)."@en . . "Moderate"@en . . . . . " "@en . . . "The elimination half-life is approximately 0.70 hours."@en . . . . . "approved"@en . . . . "Enterococcus faecalis"@en . . "Dalfopristinum"@en . . . . . . . "# Allington DR, Rivey MP: Quinupristin/dalfopristin: a therapeutic review. Clin Ther. 2001 Jan;23(1):24-44. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11219478 # Lamb HM, Figgitt DP, Faulds D: Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections. Drugs. 1999 Dec;58(6):1061-97. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10651391 # Manzella JP: Quinupristin-dalfopristin: a new antibiotic for severe gram-positive infections. Am Fam Physician. 2001 Dec 1;64(11):1863-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11764864 # Paradisi F, Corti G, Messeri D: Antistaphylococcal (MSSA, MRSA, MSSE, MRSE) antibiotics. Med Clin North Am. 2001 Jan;85(1):1-17. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11190346"@en . . . "Dalfopristin is a combination of two antibiotics (Dalfopristin and quinupristin) used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium. It is not effective against Enterococcus faecalis infections. Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosome and quinupristin inhibits the late phase of protein synthesis."@en . . . . . "112362-50-2"@en . . . . . . . "Enteric bacteria and other eubacteria"@en . . "Dalfopristine"@en . "Dalfopristin"@en . .